Literature DB >> 18359116

L347P PINK1 mutant that fails to bind to Hsp90/Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner.

Yasuhiro Moriwaki1, Yeon-Jeong Kim, Yukari Ido, Hidemi Misawa, Koichiro Kawashima, Shogo Endo, Ryosuke Takahashi.   

Abstract

Mutation of PTEN-induced kinase 1 (PINK1), which encodes a putative mitochondrial serine/threonine kinase, leads to PARK6, an autosomal recessive form of familial Parkinson's disease. Although the precise function(s) of PINK1 protein is unknown, the recessive inheritance of this form of Parkinson's disease suggests loss of PINK1 function is closely associated with its pathogenesis. Here we report that PINK1 forms a complex with the molecular chaperones Hsp90 and Cdc37/p50 within cells, which appears to enhance its stability. When cells were treated with an Hsp90 inhibitor (geldanamycin or novobiocin), levels of PINK1 were greatly diminished, reflecting its rapid degradation via ubiquitin-proteasome pathway. Similarly, the half-life of a pathogenic PINK1 mutant (L347P) that did not interact with Hsp90 or Cdc37/p50 was only 30min, whereas that of wild-type PINK1 was 1h. These results strongly suggest that Hsp90 and Cdc37 are binding partners of PINK1 which regulate its stability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359116     DOI: 10.1016/j.neures.2008.01.006

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  39 in total

Review 1.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

2.  The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization of protein kinase C through a conserved PXXP motif in the C-terminal tail.

Authors:  Christine M Gould; Natarajan Kannan; Susan S Taylor; Alexandra C Newton
Journal:  J Biol Chem       Date:  2008-12-17       Impact factor: 5.157

3.  PINK1 is degraded through the N-end rule pathway.

Authors:  Koji Yamano; Richard J Youle
Journal:  Autophagy       Date:  2013-04-17       Impact factor: 16.016

Review 4.  Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models.

Authors:  Ruben K Dagda; Jianhui Zhu; Charleen T Chu
Journal:  Mitochondrion       Date:  2009-06-27       Impact factor: 4.160

Review 5.  Parkinson's disease: what the model systems have taught us so far.

Authors:  Swagata Ghatak; Dorit Trudler; Nima Dolatabadi; Rajesh Ambasudhan
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

6.  Chemical inhibition of FBXO7 reduces inflammation and confers neuroprotection by stabilizing the mitochondrial kinase PINK1.

Authors:  Yuan Liu; Travis B Lear; Manish Verma; Kent Zq Wang; P Anthony Otero; Alison C McKelvey; Sarah R Dunn; Erin Steer; Nicholas W Bateman; Christine Wu; Yu Jiang; Nathaniel M Weathington; Mauricio Rojas; Charleen T Chu; Bill B Chen; Rama K Mallampalli
Journal:  JCI Insight       Date:  2020-06-04

7.  PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K/AKT pathway.

Authors:  Ruth Mélida Sánchez-Mora; Humberto Arboleda; Gonzalo Arboleda
Journal:  J Mol Neurosci       Date:  2012-01-03       Impact factor: 3.444

8.  Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.

Authors:  Diogo Martins Branco; Daniela M Arduino; A Raquel Esteves; Diana F F Silva; Sandra M Cardoso; Catarina Resende Oliveira
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

9.  Heat shock protein 90 in neurodegenerative diseases.

Authors:  Wenjie Luo; Weilin Sun; Tony Taldone; Anna Rodina; Gabriela Chiosis
Journal:  Mol Neurodegener       Date:  2010-06-03       Impact factor: 14.195

Review 10.  Protein homeostasis as a therapeutic target for diseases of protein conformation.

Authors:  Barbara Calamini; Richard I Morimoto
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.